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Summary  21 
Cross-sectorial surveillance and general collaboration between the animal and the public health 22 
sectors are increasingly recognized as needed to better manage the impacts of zoonoses. From 23 
2009, the Swiss established a Campylobacter mitigation system that includes human and poultry 24 
surveillance data sharing within a multi-sectorial platform, in a “One Health” approach. The 25 
objective of this study was to explore the economics of this cross-sectorial approach, including 26 
surveillance and triggered interventions. Costs and benefits of the “One Health” and of the uni-27 
sectorial approach to Campylobacter surveillance were identified using an economic assessment 28 
framework developed earlier. Cost information of surveillance activities and interventions was 29 
gathered and Disability Adjusted Life Years (DALYs) associated to the disease estimated for 2008 30 
and 2013. In the first five years of this “One Health” approach to Campylobacter mitigation, 31 
surveillance contributed with information mainly used to perform risk assessments, monitor 32 
trends and shape research efforts on Campylobacter. There was an increase in costs associated 33 
to the mitigation activities following integration, due to the allocation of additional resources to 34 
research and implementation of poultry surveillance. The overall burden of campylobacteriosis 35 
increased by 3.4-8.8% to 1751- 2852 DALYs in 2013. In the timing of the analysis, added value 36 
associated to this cross-sectorial approach to surveillance of Campylobacter in the country was 37 
likely generated through non-measurable benefits such intellectual capital and social capital.  38 
 39 
Key results:  40 
• The information generated by the “One health” approach to surveillance in the period of the 41 
study was mainly used to perform cross-sectorial risk assessments and to identify research 42 
needs.  43 
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• The implementation of a “One Health” approach to Campylobacter to disease mitigation 44 
activities in the period 2009-2013 in Switzerland had associated increased costs. The main part 45 
of resources was allocated to commissioned research on Campylobacter.  46 
• Non-measurable benefits such as social and intellectual capital were associated with the multi-47 
sectorial approach to Campylobacter surveillance in the first five years of this system. 48 
• The estimated burden of disease in the country was of 1751-2852 DALYs in 2013, an increase 49 
when compared to 2008.  50 
• Overall the framework used provided a practical tool to identify and estimate costs and benefits 51 
associated with surveillance of Campylobacter in a “One Health” context. 52 
 53 
54 
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Introduction 55 
Campylobacter poses an important public health threat, and it is currently identified to be the 56 
most important zoonotic infectious agent in Europe [1]. In Switzerland, human 57 
campylobacteriosis has been a notifiable disease since 1988 and the most frequently recorded 58 
zoonotic infection since 1995. Overall, an increasing trend of the disease in humans has been 59 
observed, with a peak of notified cases of 105 reports per 100’000 inhabitants in 2012 [2,3]. Its 60 
impact in the country in terms of healthcare costs of laboratory-confirmed campylobacteriosis 61 
patients has been recently estimated to be of 8.3 million Euros [4]. There is a distinct two-peak 62 
seasonality of reported human cases in the country: a summer peak, likely to be connected to a 63 
higher infection rate in poultry flocks, higher frequency of exposure via barbecue activities and 64 
travels abroad, and a winter peak mainly related to consumption of chicken meat in the 65 
traditional festive dish “Fondue Chinoise” [5–7]. The chicken reservoir has been identified as the 66 
main source for human campylobacteriosis in Switzerland, with 71% of the human cases 67 
attributed to chickens based on the comparison of isolates from humans and animals [8]. In 68 
poultry, the prevalence of Campylobacter in cloacal swabs ranged from 33% to 38%, from 2010 69 
to 2013 [6].   70 
 71 
In response to the observed increasing trend in human campylobacteriosis cases, the animal 72 
and the human health authorities enhanced collaborative disease surveillance and intervention 73 
efforts with the intention of improving the disease management. A stakeholder group 74 
composed by the poultry industry, researchers and public health and animal health national and 75 
cantonal authorities – the Campylobacter platform – was formed with the aim of exchanging 76 
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information, coordinating and evaluating control measures, and to identify gaps of knowledge 77 
and funding of research [2]. A regular surveillance system in broiler chicken was also 78 
implemented. This constituted a shift from the previously instituted system, which was 79 
essentially based on the monitoring of human cases.  80 
 81 
Such change, from a uni-sectorial to a multi-sectorial approach to Campylobacter mitigation, is 82 
also in line with an increased recognition at the international level of the need for collaboration 83 
between the animal and the public health sectors as a means to improve the management of 84 
zoonotic threats.  The “One Health” movement is based on the principles that collaborative or 85 
integrated efforts across multiple disciplines can result in a decrease of the burden of zoonotic 86 
disease and generate a better health status, and that a multi-sectorial approach best captures 87 
the interrelationships of health of different species [9,10]. This includes strengthened integrated 88 
surveillance systems for zoonotic pathogens and sharing of information, currently seen as key to 89 
an effective health system [11–14].  90 
 91 
The need to identify better ways to mitigate the impact of campylobacteriosis has triggered 92 
research work into the cost-effectiveness of control options for Campylobacter at different 93 
levels of the food chain in different countries [15–17]. However, similar to economic 94 
assessments of other zoonotic diseases, the focus of these assessments is largely on the 95 
economics of disease control, with no specific focus on the costs and benefits of efforts for 96 
surveillance or collaborative mitigation activities for Campylobacter. Surveillance activities 97 
require resource spending that may be significant and information on the extent of expenditure 98 
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associated to these activities is needed to inform prevention, surveillance and control strategy 99 
decisions. Furthermore, from an economics perspective, it is of interest to consider whether 100 
overall resources are used more efficiently by integrated, “One Health” surveillance, than by a 101 
surveillance system with disconnected, sector-specific components. Such increased efficiency in 102 
resource use can be attained either through cost savings and/or by added benefits associated to 103 
a reduced impact at a societal level of zoonotic threats [18].  104 
 105 
It has been shown in previous work that the economic assessment of surveillance activities 106 
needs to be underpinned by the understanding of how the surveillance activities link to 107 
interventions and to the broader mitigation process [19]. An assessment of the overall 108 
mitigation approach including surveillance and intervention is therefore needed when exploring 109 
the economics of surveillance. In the case of “One Health surveillance”, this extends to the 110 
understanding of how surveillance information is used and how it triggers health consequences 111 
and benefit streams across different sectors [18].   112 
 113 
In this study, we explored the cross-sectorial costs and benefits associated with the sharing of 114 
surveillance information on Campylobacter in Switzerland in the period of 2009-2013. The 115 
objective is to provide information on the economics of this cross-sectorial approach to 116 
Campylobacter mitigation and to test the practical implementation of an assessment framework 117 
previously developed.  118 
 119 
Methods 120 
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 121 
General approach  122 
The “One Health” approach to Campylobacter mitigation was considered as the system in place 123 
since 2009 to 2013 (in this study). In this period information generated by surveillance activities 124 
in the poultry population and in the human population was shared in the Campylobacter 125 
platform and fed into cross-sectorial policy discussions, triggering public health and animal 126 
health targeted interventions. The collaborative nature of the analysis of information generated 127 
by the animal and the human surveillance streams in the Campylobacter platform fits into the 128 
concept of “One Health surveillance”, as currently described [20,21]. This “One Health” 129 
approach was compared with the system in place prior to the Campylobacter platform 130 
establishment, the 5 years-period from 2004 to 2008. The mitigation activities during this period 131 
were predominantly public-health-based, with a monitoring system centered on mandatory 132 
notification of human cases, triggering public health messaging activities.  133 
 134 
As mentioned before, costs and benefits of surveillance are intrinsically linked to the 135 
interventions triggered by the information generated. Taking this into consideration, and to 136 
guide our assessment, we applied a framework previously developed [18] to identify 137 
surveillance activities across the two sectors, their links to public health and animal health 138 
decision making and triggered interventions in the two periods of time. The framework entails 139 
an initial step that involves a conceptualization of the links between surveillance and triggered 140 
interventions, followed by the identification of costs and benefits and their valuation. An 141 
overview of the steps taken in this analysis is provided in Figure 1. 142 
 143 
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Figure 1. Overview of the steps taken in the economic assessment of Campylobacter surveillance in Switzerland in a “One 144 
Health” perspective following the conceptual framework used in this study [18]. 145 
 146 
Only official surveillance systems and interventions were considered in this assessment and 147 
industry-borne costs and benefits were not incorporated in the analysis. 148 
 149 
Initial framing and identification of cost and benefit items associated to Campylobacter 150 
surveillance 151 
The initial framing for the analysis entailed the conceptualization of the links between the 152 
surveillance streams for Campylobacter and the triggered interventions across sectors. 153 
Information on the type of surveillance activities, integration mechanisms and interventions 154 
prompted by the information generated in both the animal and the human health sectors were 155 
identified for the “One Health” and uni-sectorial systems, based on discussion with experts 156 
involved in the surveillance activities and in the Campylobacter platform and literature review 157 
[2]. The information was mapped enabling the identification of the costs items and potential 158 
benefit streams of the mitigation systems (Figure 2). 159 
 160 
Valuing costs and estimating the break-even point 161 
Data used to parameterize the cost estimation model were collected for the two periods in 162 
analysis from the Swiss Federal Food Safety and Veterinary Office (FVO) and Federal Office of 163 
Public Health (FOPH). Labour costs and expenses accrued by planning and preparation tasks of 164 
the surveillance systems, sampling and test costs, including analysis and transport of materials 165 
and samples were included where appropriate, as well as labour costs and expenses related to 166 
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data analysis and interpretation, and information dissemination. Running costs of the 167 
Campylobacter platform as well as costs associated with interventions that were triggered by 168 
surveillance information were also estimated. For the human monitoring system, only labour 169 
and expenses associated with the notification of cases upstream from the laboratory diagnosis 170 
were considered, as all costs downstream to that point could not be directly allocated to the 171 
monitoring system. Intangible costs were not included in the analysis. Table 1 summarizes the 172 
inputs considered for the cost estimate. 173 
 174 
Labour costs for scientific and administrative level staff were calculated considering the wage 175 
table established by the Swiss Confederation for 2014 and using an average variation of 1.2% 176 
[22] to establish the corresponding wages for the years in analysis. A working month of 182.7 177 
hours was used as a basis for the calculation of the hourly cost associated with the 178 
Campylobacter mitigation activities.  179 
 180 
The break-even point for the system, i.e. the point at which cost or expenses and benefits are 181 
equal and the system would recover its costs, was calculated in terms of the number of DALYs - 182 
the metric used to assess marginal benefits of the system - that would have to be averted. To 183 
compare a monetary metric for costs (Swiss Francs [CHF]) with a non-monetary metric, break-184 
even points were calculated using three point estimates of health burden and associated cost-185 
of-illness (converted into CHF, using the yearly average exchange rate of 2013) available in the 186 
literature: 8’437 CHF/DALY [23], 61’362 CHF/DALY [24] (considering the average DALY estimate) 187 
and 21’534 CHF/DALY [25].  188 
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Valuing benefits 189 
From the benefit streams identified (Figure 2), we explored in more detail potential changes in 190 
the impact of disease in the human population. The potential benefits of Campylobacter 191 
mitigation in the poultry population, in terms of direct impact, were not assessed considering 192 
the relatively minor role of Campylobacter as a pathogen for poultry [26]. Similarly, potential 193 
benefits in terms of mitigation of potential indirect impacts (e.g. effects on market access and 194 
trade) were not assessed.  195 
 196 
Burden of disease was calculated using DALYs, applying the methodology developed by Murray 197 
& Lopez [27] and building upon the model recently used in Denmark for the estimation of the 198 
burden of foodborne disease [28]. The estimates of burden for 2013 (5 years after the start of 199 
the approach) were compared to the estimated burden of disease in 2008 (the year prior to the 200 
implementation of the Campylobacter platform).  201 
 202 
Table 2 summarizes the inputs used to parameterize the DALY model. To correct for 203 
underdiagnoses and underreporting and estimate the total incidence of disease in the 204 
community, multiplication factors of 3.4 [23] and of 9.3 [29] as a best and worst case scenario 205 
were used in the two years estimated - 2008 and 2013. Underreporting and underdiagnoses 206 
were considered as constant in 2008 and 2013 as there were no changes to the human 207 
monitoring system. Health outcomes associated with Campylobacter infection considered were 208 
gastroenteritis (GE), reactive arthritis (RA), irritable bowel syndrome (IBS), inflammatory bowel 209 
disease (IBD) and Guillain-Barre Syndrome (GBS). Data pertaining to these health outcomes 210 
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were sourced from national data whenever possible and from data available in the literature 211 
from elsewhere and recently reviewed in [28]. The disability weights (DW) used were based on 212 
the Global burden of disease 2010 study [30]. When the DW for a specific health outcome was 213 
not available, a DW from an outcome with similar health effects was used. When DWs for 214 
specific health outcomes differentiated between multiple degrees of severity, an overall DW 215 
was calculated on the basis of the estimate of the proportion of cases with those severity levels 216 
in Switzerland. Life expectancy estimates were obtained from the Swiss population statistics for 217 
2013 [31]. Age weighting and discounting were not applied. 218 
 219 
Total years of life lost to disability (YLD), to mortality (YLL), and overall DALYs for the years in 220 
analysis were calculated by applying a stochastic model using the DALY Calculator interface 221 
developed in R [38]. In addition to the estimate of best and worst case scenarios to explore the 222 
uncertainty resulting from data limitations in the incidence of Campylobacteriosis, sensitivity 223 
analysis using a linear regression-based analysis was conducted in the same software to explore 224 
the contribution of each stochastic variable in model input parameters to the overall 225 
uncertainty of the end result. 226 
 227 
Results  228 
From 2009 to 2013, the information generated by surveillance in the animal population and by 229 
human cases monitoring shared in the Campylobacter platform, triggered activities concerning 230 
biosecurity messaging in poultry farms and public health messaging on hygienic measures for 231 
chicken meat handling and prevention of cross-contamination. Integration of surveillance 232 
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information was also used to perform cross-sectorial risk assessments and to identify gaps in 233 
the knowledge base for Campylobacter infection in the country and research needs.  The links 234 
between information generated by the animal health sector and triggered interventions in the 235 
public health sector through the integration of this information in a “One Health” approach are 236 
represented in Figure 2.  237 
 238 
Figure 2. Conceptual representation of the links between Campylobacter surveillance and triggered activities across the public 239 
health and the animal health sectors and the benefit streams generated, in 2009-2013. 240 
 241 
Through its links to public health messaging, surveillance of Campylobacter in poultry and 242 
integration of information has the potential to generate a reduction in the direct and indirect 243 
impact of the disease in the human population, namely on the burden of disease or cost-of-244 
illness. Equally, through its links to biosecurity messaging at farm level, it has the potential to 245 
reduce the direct and indirect impact of disease in the animal population, ultimately 246 
contributing to a reduction in human infection.  247 
 248 
Intermediate or intangible benefits were identified, related to enhanced knowledge, 249 
performance of risk assessments and triggering of research, such as intellectual capital, and to 250 
social capital, generated through the intrinsic value of multi-sectorial collaboration and 251 
networking. 252 
 253 
The overall mitigation activities surrounding Campylobacter in Switzerland in the period 2009-254 
2013 had an associated cost of approximately 1.85 million CHF, corresponding to a yearly 255 
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average expenditure of approximately 370’000 CHF. This figure does not include mitigation 256 
costs borne by industry as these were not available but known to be >0. The overall marginal 257 
cost of such an enhanced effort was of 1.2 million CHF (over 5 years) in relationship with the 5-258 
year period 2004-2008 when the activities were mainly public-health based. Almost half (48%) 259 
of the total expenditure in 2009-2013 was absorbed by commissioned research on 260 
Campylobacter in Switzerland, followed by the surveillance and monitoring activities in poultry 261 
and humans respectively. Table 3 shows the cost analysis results by system component for the 262 
“One Health” approach. 263 
 264 
The average total burden of disease of campylobacteriosis was estimated to be 1751 (95% 265 
Confidence Interval (CI): 1478, 2069) to 2852 (95% CI: 2520, 3227) DALYs in 2013, in the best 266 
and worst case scenarios respectively. This represents a 3.4-8.8% increase since 2008 when the 267 
estimated burden of disease was of 1609 (95% CI: 1330, 1947) DALYs to 2756 (95% CI: 2412, 268 
3140) (undiscounted). From the total results, 746-802 to 820-942 of the DALYs were related to 269 
GE in 2008 and in 2013, respectively, with the remaining burden allocated to the disease 270 
sequelae. The total DALYs correspond to 20.19-34.59 and to 21.96-35.08 DALYs/100’000 271 
inhabitants in 2008 and 2013 respectively. Table 4 shows these results in more detail.  272 
 273 
The “One Health” mitigation approach would recover its costs if 6 to 43.8 DALYs were averted 274 
per year, depending on the cost-of-illness to DALY match estimate used in the break-even point 275 
calculations.  276 
 277 
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Figure 3 summarizes the results of the cost analysis and burden calculation by showing the 278 
evolution of costs per activity in the 10 years of the analysis and the campylobacteriosis burden 279 
estimate from 2008 to 2013. 280 
 281 
Figure 3. Costs of Campylobacter mitigation activities in Switzerland per activity undertaken, from 2004 to 2013 (CHF) and 282 
estimates of overall campylobacteriosis burden of disease (DALYs) for 2008 and 2013 (best and worst case scenarios for 283 
estimated true incidence).  284 
 285 
In addition to the impact of the estimated true incidence input parameter showed above, the 286 
sensitivity analysis indicated that, from the stochastic inputs to the model, changes in the 287 
duration of symptoms of GE had the highest impact on the model outcome. One standard 288 
deviation change in duration of GE symptoms would lead to a difference of 34.2 DALYs in the 289 
overall DALY estimate.  290 
 291 
Discussion 292 
We assessed the costs and benefits associated with Campylobacter surveillance in Switzerland 293 
from a “One Health” perspective.  294 
 295 
Our results suggest that, in the first five years of the system, the level of the expenditure 296 
increased with a cross-sectorial approach to surveillance and intervention for Campylobacter in 297 
the country, particularly in research funding and surveillance activities in poultry. In the period 298 
of this work, integrated surveillance information contributed mainly to the assessment of 299 
trends, to perform risk assessments and to inform discussion on gaps and information needs 300 
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regarding Campylobacter in the country, thus contributing to the shaping of research efforts 301 
and strengthening of the knowledge base regarding the disease. Consequently, in these initial 302 
five years, the nature of benefits was intangible, including the generation of intellectual capital. 303 
The latter relates to the intangible value (information, intellectual property, experience) in the 304 
knowledge and relationships of employees, management staff, and other stakeholders of a 305 
company or institution, that can be used, in the future, to generate wealth. In the public sector 306 
context, measurement of intellectual capital and knowledge assets has been carried out by 307 
universities and research funding institutions [39].  308 
 309 
Such intellectual capital created by surveillance can later generate measurable value when it is 310 
translated into control measures that mitigate the impact of the disease. In fact, from 2014, the 311 
Campylobacter mitigation system in Switzerland shifted from a main focus on assessment and 312 
knowledge-generation to the implementation of interventions targeting the food chain. New 313 
national regulations in place from January 2014 require that poultry liver from Campylobacter-314 
positive herds can only be sold frozen and that pre-packed fresh poultry meat and meat 315 
preparations should be labeled with information on the need to thoroughly cook the products 316 
before consumption and on hygiene rules [6].  317 
 318 
The timing of our analysis is therefore particularly relevant for the benefits assessment. A time 319 
delay between initiating research and implementing interventions with possible health effects 320 
can be expected.  Furthermore, it can be expected that the power of an integrated surveillance 321 
system increases with time as information is gathered and trends and sources are more 322 
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accurately identified. This has been shown with other integrated surveillance approaches such 323 
as the Danish Integrated Antimicrobial Resistance Monitoring Programme [40] 324 
 325 
The estimated burden of disease increased from 1609-2756 in 2008 to 1751-2852 DALYs in 326 
2013. The increase of overall burden of disease in Switzerland of 96 to 142 DALYs from 2008 to 327 
2013 reflects not only an increase in overall incidence of disease, but also a shift in the age 328 
structure of cases, with a steady increase of case reports among the elderly aged above 65, 329 
where the Campylobacter associated mortality rate is higher, from 49/100‘000 inhabitants in 330 
2004 to 100/100‘000 in 2013 [6]. Simultaneously, an increase in chicken meat consumption 331 
from 10.88 to 11.42 kg per capita has been observed in the country over the same period 332 
(Proviande data). Such increase needs to also be interpreted considering that in the period of 333 
this analysis there was no direct control interventions implemented in the food chain, and 334 
therefore a direct health effect and measurable benefit of surveillance in this timeframe would 335 
not be expected. Additional economic analysis further in time could allow understanding if 336 
measurable benefits are generated by the intervention measures implemented from 2014 337 
described above. Such benefits could be quantified by assessing the effect of the interventions 338 
and by comparing it with baseline scenarios as described in studies estimating the cost-339 
effectiveness of interventions targeting Campylobacter along the food chain (reviewed in [23]). 340 
Increasing the timeframe would allow to capture possible measurable health effects and to 341 
estimate cost-effectiveness of the “One Health” when compared to uni-sectorial approaches. 342 
 343 
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The break-even point analysis for the “One Health” approach suggests that a return on 344 
investment can be achieved with a small reduction in cases reported. Although this information 345 
provides a perspective on how intervention costs can be recouped, it does not provide evidence 346 
on how this system compares in terms of costs per DALY avoided with other mitigation system 347 
designs. For Campylobacter in particular, a reduction in cases does not seem to be easily 348 
achievable [41] as shown by the increasing trends on disease incidence until 2012 in most 349 
countries facing this challenge. Interventions in the poultry meat production chain, such as 350 
biosecurity alone, have limited effect and the most effective interventions such as freezing are 351 
costly and face consumer acceptance constrains [41].  352 
 353 
Some limitations to our estimates can be considered. The cost analysis and results for marginal 354 
cost increase associated to the cross-sectorial mitigation efforts for Campylobacter in this study 355 
focused on official surveillance programmes and interventions reliant on public spending. Yet, in 356 
addition to the official surveillance and control activities, the poultry industry has also been 357 
carrying out mitigation activities to tackle Campylobacter at pre-harvest and post-harvest levels. 358 
Since our estimates do not account for the costs of such activities, our results are likely an 359 
underestimation of the societal efforts in terms of expenditure in Campylobacter surveillance 360 
and mitigation. In the same way, we did not exhaustively assess all benefit streams potentially 361 
linked to surveillance integration. Fluctuations in terms of consumption and production due to 362 
trade at the country level and potential alleviation effects on changes in consumer perception 363 
and loss of sales could have implications in the overall benefits assessment from a societal 364 
perspective. Benefits could therefore also be undervalued in this study. 365 
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 366 
Our DALY estimates of 21.98-35 DALYs/100’000 inhabitants in 2013 are in agreement with 367 
results recently observed elsewhere in Europe. For other countries, the most recent estimates 368 
point to a burden of campylobacteriosis of 19.8 DALYs/100’000 in the Netherlands [33] and of 369 
28.4 DALYs/100’000 in Denmark [28].  However, the burden of disease estimation in this study 370 
was limited by the fact that many parameters in the DALY model relied on assumptions and 371 
data sourced from literature of studies developed elsewhere. Particularly, the underreporting 372 
factor used to estimate the true incidence of Campylobacter associated disease in the human 373 
population may be influential. In our estimation, we used a multiplier factor available in the 374 
literature for Switzerland [23] as a best case scenario. That value was calculated using relative 375 
risks to Swedish travelers as a proxy for relative incidence in local residents. There are many 376 
caveats surrounding such calculations, namely underdiagnoses of travel-related cases, late 377 
expression of symptoms and inability to attribute cases to countries, absence of information on 378 
the nature and duration of travel and immunity in the resident population [42]. Preferably, the 379 
construction of national disease surveillance pyramids should be informed by country-specific 380 
information collected as part of multiplier studies [42] and involving data such as care seeking 381 
behavior, probabilities of stool sample submission, positive laboratorial results reporting and 382 
testing for a specific pathogen and the sensitivity of the laboratory tests [28].  Since multiplier 383 
studies are not available for Switzerland, and the reported factor was inferior to all other recent 384 
estimates of multiplier factors in Europe (reviewed in [28]), we also used a multiplier factor 385 
calculated for the United Kingdom to model a worst case scenario. Similarly, the use of a 386 
multiplier factor from another country can be disputed as differences in health care systems 387 
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may lead to bias [42]. The reliance on scenarios and data sourced from studies conducted 388 
elsewhere, suggests that the human cases monitoring system based upon case reporting was 389 
not generating sufficient information to be able to determine more accurately the burden of 390 
disease in the country. Future burden of disease or cost-of-illness estimations would greatly 391 
benefit from information on the parameters that seem impact the model results most, notably 392 
human incidence and prevalence data. 393 
 394 
Gains in information and knowledge have been recognized as benefits from One Health 395 
approaches [43,44]. However, the lack of ability to measure the final outputs in tangible 396 
indicators means that it is infrequent to have such benefits incorporated into economic 397 
assessments. The same situation is observable in overall economic assessment of disease 398 
control [45]. We believe that to accurately understand the added value of “One Health” and 399 
surveillance integration for decision making, the assessment of these assets needs to be an 400 
integral part of the analysis. This is particularly relevant for the surveillance systems that are at a 401 
similar maturity stage, i.e. mainly informing assessment and producing knowledge, as the 402 
Campylobacter mitigation system in Switzerland in the period 2009-2013. Further work on the 403 
importance of these intangible assets generated by surveillance integration would enrichen our 404 
understanding of the economic aspects of zoonoses surveillance and policy making.  405 
 406 
Overall, the framework used as the basis for economic assessment allowed the identification of 407 
cross-sectorial cost items and benefits streams, associated to Campylobacter in Switzerland in 408 
the period in analysis, through the conceptualization of its links to intervention. By providing 409 
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information on the economics of cross-sectorial surveillance of Campylobacter as well as the 410 
tools for this assessment, the results of this work can be directly applicable and can inform 411 
planning of effective and efficient future surveillance programmes for zoonoses. Such 412 
assessments require an understanding of how information generated by surveillance is part of 413 
the zoonoses mitigation process, and availability of data on costs of activities conducted and on 414 
the impacts of such activities in terms of intangible and tangible benefits. The latter set of 415 
benefits can only be accurately assessed if adequate surveillance information allows capturing 416 
changes in disease dynamics in the populations.  417 
 418 
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Figure 3  574 
 575 
 576 
 577 
 578 
 579 
 580 
Table 1. Inputs considered for the cost analysis per system component 581 
Mitigation system component Inputs considered for cost calculation 
Surveillance programme in poultry 
Working time involved in sample size calculation and sampling plan, 
planning of activities, sampling, data analysis, report writing, and 
dissemination activities; expenses with transport of sampling material, 
tests, shipment of samples and translation. 
Monitoring programme of cases in 
humans 
Working time involved in data management, analysis and 
dissemination. 
Campylobacter platform 
Working time involved in preparation and participation in meetings, 
and post-meeting activities including reporting of outcomes; expenses 
with transport costs. 
Pre-harvest interventions Working time on leaflets development and dissemination activities; expenses with printing. 
Post-harvest interventions and 
research funding 
Working time and expenses on commissioned research and public 
health messaging  activities. 
 582 
 583 
 584 
 585 
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Table 2. Inputs parameters for DALYs calculation and data sources 586 
Parameter Input Source 
Incidence of human 
campylobacteriosis   Reported cases per year and per age group (2004-2013) 
FOPH   
Underdiagnoses and 
underreporting factor 3.4 and 9.3 
[23,29] 
Health outcomes 
GE* 
Estimated true incidence 
FOPH & 
multiplying 
factors 
Mortality. Calculated based on excess 
mortality risk for laboratory-confirmed 
cases (0.9). This multiplier was applied to 
age-specific mortality risk by all causes 
(Statistics Netherlands’ data used as 
surrogate) 
[32,33] 
RA** 
Calculated based on: 
- Probability of having RA for a GE patient 
visiting a GP (RiskBeta (46;565)), 
- Probability of a patient with RA seeking 
care for (RiskBeta (10;37)), 
- Probability of hospitalization for RA 
patients who visit a GP (RiskBeta (2;45)) 
[33] 
IBSµ Pert (7.2; 8.8; 10.4) [34] 
IBD# Calculated based on the age specific risk of IBD and the excess risk IBD [33] 
GBS^ Beta(60;29,942) Mortality: RiskPert (0.01;0.02;0.05) [35] 
Duration of illness (years) GE (diarrhea) Pert (0.007;0.02;00.9) [5] 
RA 0.608219178 [36] 
IBS 5 [34] 
IBD Life-long [25,37] 
GBS Life-long [35] 
Disability weight  
GE (diarrhea) 
Mild: 0.061 [30] 
Moderate: 0.202 
Severe: 0.281 
Overall: 0.1049555 
RA 0.21 [30] 
IBS 0.042 [34] 
IBD 0.26 [25,37] 
GBS 0.445 [35] 
Life expectancy Men: 80.5 / Women: 84.8 /Average: 82.65 Swiss statistics 
Onset of disease and 
average age at death  Average age of the population group 
 
Hospitalization 14.5% [5] 
*GE: gastroenteritis; **RA: reactive arthritis; µIBS: irritable bowel syndrome; #IBD: irritable bowel disease; ^GBS: Guillian-Barré syndrome. 587 
588 
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Table 3. Estimated cumulative cost of the “One Health” mitigation system per component, in the period 589 
2009-2013 (in CHF) 590 
 591 
 592 
 593 
 594 
 595 
 596 
 597 
 598 
 599 
 600 
601 
Mitigation system component Estimated cost in CHF,  2009-2013 
Surveillance programme in poultry 531'000 
Monitoring programme of cases in 
humans 358'570 
Campylobacter platform 66’700 
Pre-harvest interventions 8’340 
Post-harvest interventions and research 
funding 884´900 
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Table 4. Estimated total DALYs, YLD and YLL associated with campylobacteriosis in Switzerland in 2008 602 
and 2013 in two scenarios of estimated total incidence (BCS: best case scenario; WCS: worst case 603 
scenario). The results are expressed in mean and 95%CI 604 
 605 
 2008 2013 
Reported cases 7384 7473 
Estimated total cases BCS 27906 (27534,28281) 28442 (28064, 28828) 
WCS 75516 (74889,76137) 76470 (75838, 77090) 
Estimated deaths BCS 50 (37,65) 64 (49,80) 
WCS 49 (36,73) 64 (49,80) 
DALY total BCS 1609 (1330, 1947) 1751 (1478, 2069) 
WCS 2756 (2412,3140) 2852 (2520, 3227) 
DALY/case BCS 0.057 0.061 
WCS 0.036 0.037 
DALY /100,000 BCS 20.32 21.98 
WCS 34.59 35.08 
YLD BCS 926 (774,1102) 990 (842,1163) 
WCS 2071 (1844,2335) 2075 (1842,2339) 
YLL BCS 678 (451,970) 757 (540,1031) 
WCS 681 (437,972) 781 (549,1058) 
 606 
 607 
 608 
 609 
